MUNICH--MediGene, a late-stage biopharmaceutical company developing drugs and technologies against disease targets in the areas of cancer and cardiology, completed a $25.7 million private placement involving institutional and private investors last week. The financing includes options for convertible loans of $2.3 million and a long-term loan of $6.6 million. Participants included Deutsche Bank, Dresdner Bank, Bankhaus Vontobel, Atlas Venture, Dieckell GmbH, Merifin Capital, and TBG der Deutschen Ausgleichsbank. Participating existing shareholders included Techno Venture Management, Star Ventures, Alpinvest, and a private investor group.
MediGene Raises $26M In Private Placement
Nov 21, 1998